Nancy Lee, MD - ASTRO

More documents

Recommendations

Info

EORTC 24891 LARYNX PRESERVATION FOR HYPOPHARYNGEAL CA. CA (J.L. Lefebvre et al, JNCI 88:1685-90, 1996) S + RT CT+ RT+ S No. of patients 94 100 5-yr 5 yr. DD-FF Survival 27% 25% 5-yr. Survival 35% 30% Distant Mets. 36% 25% 5-yr. y Alive with Larynx y --- 17%
Hypopharynx yp p y
Page 1 and 2:
Head and Neck II: Oropharynx, Laryn
Page 4 and 5:
OROPHARYNX-Sites Base of tongue Sof
Page 6 and 7:
INCIDENCE OF LYMPH NODE METASTASES
Page 8 and 9:
CA. OF THE OROPHARYNX INCIDENCE OF
Page 10 and 11:
Oropharyngeal CA: Treatment Volume
Page 12 and 13:
RTOG 73-03 Oral Cavity And Orophary
Page 14 and 15:
Surgery and Adjuvant RT vs. CCRT in
Page 16 and 17:
Stage III/IV Head and Neck CA: Rand
Page 18 and 19:
CA. OF THE TONSILLAR REGION LOCAL C
Page 20 and 21:
CARCINOMA OF THE TONSIL LOCAL CONTR
Page 22 and 23:
BASE OF TONGUE IMPLANTS Patient Sel
Page 24 and 25:
BASE OF TONGUE IMPLANTS Dose to the
Page 26 and 27:
Trans-Tasman Radiation Oncology PPo
Page 28 and 29:
RTOG 90-03 PHASE III STUDY OF ALTER
Page 32 and 33:
CB: 33% Late Grade 3-4 Toxicity
Page 34 and 35:
• N=77 • IV=83% RTOG 99-14 Ang
Page 36 and 37:
Gortec French Study DDenis i et t a
Page 38 and 39:
French Trial: Oropharyngeal CA (D (
Page 40 and 41:
There is also site-specific orophar
Page 42 and 43:
Why shouldn’t we just treat all a
Page 44 and 45:
Chemoradiotherapy: Late FT Dependen
Page 46 and 47:
Chemoradiotherapy: Late FT Dependen
Page 48 and 49:
An example of patient with late eff
Page 50 and 51:
Historical RT Dose Escalation • I
Page 52 and 53:
IMRT in the Treatment of Oropharyng
Page 54 and 55:
Patients Population From 9/1998 to
Page 56 and 57:
Local Control 3-year 94.4% 5-year 9
Page 58 and 59:
Local Failure versus T-stage • T1
Page 60 and 61:
Toxicities : Acute • Mucositis gr
Page 62 and 63:
IMRT for oropharynx: available data
Page 64:
Mean Doses Right Parotid 19.80 Gy R
Page 70 and 71:
% >G2 LENT SOM Subjective Xerostomi
Page 72 and 73:
Conclusions • RT preferred f d ov
Page 74 and 75: Conclusions • Careful selection o
Page 76 and 77: T1 T1-2NO 2NO Gl Glottic tti Cancer
Page 78 and 79: T1 Carcinoma of the Glottis Local C
Page 80 and 81: LOCAL CONTROL OF T1 LESIONS Locall
Page 82 and 83: T2 Carcinoma of the Glottis Local o
Page 84 and 85: LOCAL CONTROL OF T2 LESIONS Control
Page 86 and 87: LOCAL CONTROL FOR T2 LESIONS Local
Page 88 and 89: Randomized trial on RT fraction siz
Page 90 and 91: Meta-analysis of Impaired VC Mobili
Page 92 and 93: RTOG 91-11 Phase III Trial to Prese
Page 94 and 95: T4 T4a: Thyroid Th id Cartilage C i
Page 96 and 97: Induction Chemotherapy Followed By
Page 98 and 99: Stage T3 Carcinoma of the Glottis R
Page 100 and 101: Carcinoma of the Supraglottis % LLo
Page 102 and 103: VA LARYNGEAL CA. STUDY Surgery Radi
Page 104 and 105: VA LARYNX PRESERVATON STUDY Surgery
Page 106 and 107: R A N D O M GETTEC Trial - T3 Laryn
Page 108 and 109: Does Vocal Cord Fixation Preclude N
Page 110 and 111: RTOG 91-11 Ph Phase III TTrial i l
Page 112 and 113: RTOG 91-11 Induction CCRT RT 2 year
Page 114 and 115: Squamous Cell Head and Neck Cancer
Page 116 and 117: Functional Organ Preservation with
Page 118 and 119: Wh What t is i th the bbest t RT FF
Page 120 and 121: Stage III or IV of f sq cell ll ca
Page 122 and 123: HHypopharynx h
Page 126: CConcurrent Ch Chemoradiotherapy di
show all

Nancy Lee, MD - ASTRO

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?